Table 1 Baseline characteristics of participants who had anti-S receptor-binding domain antibodies measured 2 to 10 weeks following two doses of SARS-CoV-2 vaccine.

From: Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Variable

Vedolizumab

Infliximab

p

Vaccine

 BNT162b2

40.1% (413/1031)

40.1% (914/2279)

1.0

 ChAdOx1 nCoV-19

59.9% (618/1031)

59.9% (1365/2279)

Age (years)

48.0 (35.2–61.6)

40.2 (30.1–53.1)

<0.0001

Sex

 Female

48.0% (492/1024)

45.9% (1040/2267)

0.15

 Male

51.8% (530/1024)

54.1% (1226/2267)

 Intersex

0.0% (0/1024)

0.0% (0/2267)

 Prefer not to say

0.2% (2/1024)

0.0% (1/2267)

Ethnicity

 White

89.9% (920/1023)

92.5% (2096/2266)

0.037

 Asian

6.5% (66/1023)

4.6% (104/2266)

 Mixed

2.4% (25/1023)

1.4% (32/2266)

 Black

0.5% (5/1023)

0.8% (18/2266)

 Other

0.7% (7/1023)

0.7% (16/2266)

Diagnosis

 Crohn’s disease

36.9% (380/1031)

67.2% (1531/2279)

<0.0001

 UC/IBDU

63.1% (651/1031)

32.8% (748/2279)

Duration of IBD (years)

9.0 (5.0–17.0)

8.0 (3.0–16.0)

0.00017

Age at IBD diagnosis (years)

33.5 (22.8–47.3)

27.6 (20.1–39.6)

<0.0001

Immunomodulators at vaccine

20.4% (210/1031)

57.2% (1304/2279)

<0.0001

5-ASA

33.9% (349/1031)

20.6% (469/2279)

<0.0001

Steroids

5.9% (61/1031)

2.8% (64/2279)

<0.0001

BMI

26.0 (23.0–29.8)

25.9 (22.8–30.0)

0.74

Heart disease

4.9% (50/1023)

2.6% (59/2261)

0.0011

Diabetes

7.6% (78/1023)

3.6% (82/2261)

<0.0001

Lung disease

16.4% (168/1023)

13.1% (296/2261)

0.013

Kidney disease

1.9% (19/1023)

0.8% (17/2261)

0.065

Cancer

1.6% (16/1023)

0.3% (6/2261)

<0.0001

Smoker

 Yes

8.2% (84/1023)

10.8% (245/2261)

0.0010

 Not currently

37.7% (386/1023)

30.2% (682/2261)

 Never

54.1% (553/1023)

59.0% (1334/2261)

Exposure to documented cases of COVID-19

7.8% (80/1023)

8.6% (195/2261)

0.46

Income deprivation score

0.089 (0.055 - 0.146)

0.091 (0.052 - 0.153)

0.92

Active disease (PRO2)

10.4% (102/977)

5.2% (111/2153)

<0.0001

Time between vaccine doses (weeks)

10.9 (9.7–11.1)

11.0 (10.0–11.3)

0.0030

Time from second dose to serum sample (weeks)

5.7 (3.7– 7.7)

5.7 (3.7–7.7)

0.73

  1. Values presented are median (interquartile range) or percentage (numerator/denominator).
  2. P values represent the results of a Mann–Whitney U, Kruskal–Wallis or Fisher’s exact test.
  3. UC ulcerative colitis, IBDU IBD unclassified, IBD inflammatory bowel disease, 5-ASA 5-aminosalicylic acid, BMI body mass index, PRO2 IBD disease activity.
Back to article page